Word

ARK THERAPEUTICS

Status

Dead

Status Code

710

Status Date

Friday, March 8, 2019

Serial Number

77937687

Registration Number

4184675

Registration Date

Tuesday, August 7, 2012

Mark Type

4000

Filing Date

Wednesday, February 17, 2010

Published for Opposition

Tuesday, April 3, 2012

Cancellation Date

Friday, March 8, 2019

Trademark Owner History

Ark Therapeutics Limited - Original Registrant

Classifications

1 Diagnostic protein preparations for use in science, scientific diagnostics, medical laboratory use and research; diagnostic preparations of genes for use in science, scientific diagnostics, medical laboratory use and research

5 Diagnostic protein preparations for medical use; diagnostic preparations of genes for medical use; pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely, for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutic purposes, namely, for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes, namely, for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes, namely, to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes, namely, for increasing the efficiency of muscle cell energy production; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; none of the above including dietary and nutritional supplements

10 Boots and gloves for orthopaedic and medical purposes; parts of boots and gloves for orthopedic and medical purposes, namely, heels, soles and inserts; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for boots and gloves for medical purposes, namely, for the treatment of wounds and burns; biodegradable collagen collar delivery devices for delivering therapeutic agents and gene therapy products to specific sites

42 Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; providing scientific, medical and clinical research information, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; none of the above in the dietary or nutritional supplement field

Color is not claimed as a feature of the mark.
"THERAPEUTICS"

Trademark Events

Mar 8, 2019

Cancelled Sec. 8 (6-Yr)

Aug 7, 2017

Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed

Aug 7, 2012

Registered-Principal Register

Jun 28, 2012

1(B) Basis Deleted; Proceed To Registration

Jun 28, 2012

Notice Of Allowance Cancelled

Jun 28, 2012

Case Assigned To Intent To Use Paralegal

Jun 22, 2012

Teas Delete 1(B) Basis Received

May 29, 2012

Noa E-Mailed - Sou Required From Applicant

Apr 3, 2012

Official Gazette Publication Confirmation E-Mailed

Apr 3, 2012

Published For Opposition

Mar 14, 2012

Notification Of Notice Of Publication E-Mailed

Feb 27, 2012

Law Office Publication Review Completed

Feb 21, 2012

Approved For Pub - Principal Register

Feb 10, 2012

Examiner's Amendment Entered

Feb 10, 2012

Notification Of Examiners Amendment E-Mailed

Feb 10, 2012

Examiners Amendment E-Mailed

Feb 10, 2012

Examiners Amendment -Written

Feb 1, 2012

Teas/Email Correspondence Entered

Feb 1, 2012

Correspondence Received In Law Office

Jan 10, 2012

Teas Response To Office Action Received

Jul 12, 2011

Notification Of Non-Final Action E-Mailed

Jul 12, 2011

Non-Final Action E-Mailed

Jul 12, 2011

Non-Final Action Written

Jun 21, 2011

Teas/Email Correspondence Entered

Jun 21, 2011

Correspondence Received In Law Office

Jun 15, 2011

Teas Response To Office Action Received

Dec 21, 2010

Notification Of Non-Final Action E-Mailed

Dec 21, 2010

Non-Final Action E-Mailed

Dec 21, 2010

Non-Final Action Written

Nov 30, 2010

Teas/Email Correspondence Entered

Nov 30, 2010

Correspondence Received In Law Office

Nov 29, 2010

Teas Response To Office Action Received

May 27, 2010

Notification Of Non-Final Action E-Mailed

May 27, 2010

Non-Final Action E-Mailed

May 27, 2010

Non-Final Action Written

May 20, 2010

Assigned To Examiner

Apr 9, 2010

Applicant Amendment Prior To Examination - Entered

Apr 8, 2010

Assigned To Lie

Mar 29, 2010

Teas Voluntary Amendment Received

Feb 23, 2010

New Application Office Supplied Data Entered In Tram

Feb 20, 2010

New Application Entered In Tram